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Table I. Fibrin degradation products (ng/ml) 
Source of blood Placebo Aprotinin 
Systemic circulation 1,620 + 420 970 -+ 330* 
Surgical wound 38,200 + 9,300 17,900 -+ 6,800? 
The data are presented asmean +- standard deviation. 
*p < 0.05. 
Cp < 0.01. 
aprotinin on the wound surface, proving the hypothesis 
that a stable fibrin sealing of the wound prevents postop- 
erative bleeding. 
Therefore, we conducted a study in 12 patients under- 
going coronary m-tery bypass grafting randomly treated 
with placebo or low-dose aprotinin in the pump prime. 
The blood oozing from the surgical wound was collected 
in the pericardial cavity and sampled during creation of 
the distal coronary anastomoses. Blood samples from the 
systemic irculation were taken simultaneously for com- 
parison. An enormous increase of fibrin degradation 
products was observed in the blood of the surgical wound 
compared with systemic blood (p < 0.01) (Table I). Likely, 
the increased fibrin degradation products in the blood 
from the surgical wound represents the Iysis of the fibrin 
hemostatic sealing on the wound surface. Aprotinin re- 
duced fibrin degradation products in wound blood only by 
half (p < 0.01) (Table I). This result indicates that 
systemically applied low-dose aprotinin could reduce but 
not prevent lysis of hemostatic fibrin sealing on the wound 
surface during CPB. Moreover, after closure of the tho- 
racic cavity this fibrinolytic state could be even more 
intensified by the increased activity of tissue-plasminogen 
activator from the pericardiumfi Therefore the topical use 
of aprotinin before closure of the thoracic avity could be 
most effective in preserving fibrin hemostatic sealing on 
the wound surface. The scheme for low-dose aprotinin 
was designed to preserve platelet function during CPB 3 
but not to maintain the antifibrinolytic apacity after 
closure of the thoracic cavil),. Therefore use of topical 
aprotinin might be recommended in addition to tow-dose 
use in the pump prime to amplify the hemostatic capacity 
of aprotinin by two mechanisms: preserving platelet func- 
tion during CPB and preserving fibrin hemostatic sealing 
after closure of the thoracic cavity. 
N. Tabuchi, MD 
J. de Haan, PhD 
W. van Oeveren, PhD 
Thoraxcenter 
Blood Interaction Research 
University Hospital Groningen 
Groningen, The Netherlands 
REFERENCES 
1. Edmunds LH Jr. Aprotinin use in pediatric cardiac 
operations. J THORAC CARDIOVASC SURG 1993;105: 
757-8. 
2. Edmunds LH Jr. Aprotinin's effect in cardiopulmonary 
bypass. J THORAC CARDIOVASC SURC 1993;106:748-9. 
3. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman 
L, Wildevuur CRH. Aprotinin protects platelets 
against he initial effect of cardiopulmonary b pass. J
THORAC CARDIOVASC aURa 1990;99:788-97. 
4. Tabuchi N, de Haan J, Boonstra PW, Gallandat Huet 
RCG, van Oeveren W. Aprotinin effect on platelet 
function and clotting during cardiopulmonary b pass. 
Eur J Cardiothorac Surg 1994;8:87-90. 
5. Mohr R, Goor DA, Lusk 7 A, Lavee J. Aprotinin 
prevents cardiopulmonary b pass-induced platelet dys- 
function. Circulation 1992;86(Suppl):II405-9. 
6. Tatar H, Cicek S, Demirkilic U, et al. Topical use of 
aprotinin in open heart operations. Ann Thorac Sm'g 
1993;55:659-61. 
7. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. 
Activation of fibrinolysis in the pericardial cavity dur- 
ing cardiopulmonary bypass. J THORAC CARDIOVASC 
SVRG 1993;106:828-33. 
8. de Haan J, Sch6nberger JPAM, Haan J, van Oeveren 
W, Eijgelaar A. Tissue-t3~e plasminogen activator and 
fibrin monomers ynergistically cause platelet dysfunc- 
tion during reperfusion of shed blood after cardiopul- 
monary bypass. J THORAC CARD1OVASC SURG 1993;106: 
1017-23. 
12/8/57780 
Invited letter concerning: Topical aprotinin 
To the Editor: 
The use of topical aprotinin as proposed by Tatar and 
associates 1 is based on an empiric observation and needs 
to be confirmed. The idea is interesting, but the mecha- 
nism is not clear. The data and insights presented by 
Tabuchi, de Haan, and van Oeveren 2 are very relevant 
and valuable. 
The association constant (Ki) of aprotinin and plasmin 
is 0.23 nmol/L, but it is only 30 nmol/L for kallikrein) The 
high-dose protocol (4 mg/kg load; 4 mg/kg in pump prime) 
produces blood concentrations during cardiopulmonary 
bypass (CPB) of approximately 175 to 275 KIU/ml; with 
the half-dose protocol, concentrations range from approx- 
imately 115 to 165 KIU/ml. 4 These concentrations e tab- 
lished before and during the operation are sufficient o 
completely inhibit plasmin and succeed in attenuating 
production of D-dimer, a marker of fibrinolysis. 5 In 
addition, systemic aprotinin protects the platelet glyco- 
protein Ib receptor, probably by preventing plasmin- 
induced infolding of the receptor into platelet subcannicu- 
lar canals as demonstrated by Cramer and associatesfi 
This makes the glycoprotein Ib receptor available to 
participate in the formation of the hemostatic plug to 
produce the decrease in postoperative bleeding times 
associated with systemic aprotinin. 7 Platelet activation is 
also suppressed by unknown mechanisms that may be 
related to suppression of neutrophil activation. 8 However, 
kallikrein, which accelerates the intrinsic coagulation 
pathway, is only partially inhibited by systemic aproti- 
nin,9, lo but this is sufficient o reduce thrombin formation 
during CPB. Because of the doses required, systemic 
aprotinin probably does not appreciably inhibit factor 
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VIIa-tissue factor complex of the extrinsic pathway la or 
plasmin formation. 13 
The mechanism by which aprotinin inhibits fibrinolysis 
in vivo is not precisely known. Unlike ~o-aminocarboxylic 
acids, which bind to the high-affinity l sine receptor site of 
plasminogen, ~4aprotinin interacts with the active site 
of plasmin to produce ssentially irreversible inhibition of 
the active enzyme. 15 However, in vivo fibrinolysis is a 
complicated business that involves activation of plasmin- 
ogen primarily by tissue plasminogen activator. Activation 
of free plasminogen by tissue plasminogen activator is 
slow, but fibrin strongly attracts both proteins and accel- 
erates binding, which results in plasmin formation and 
fibrinolysis. The w-amino acids block plasminogen binding 
to fibrin and, in effect, block plasmin formation but do not 
directly inhibit plasmin. 14 Aprotinin competes with fibrin 
for the active site of plasmin and in thepresence of fibrin 
inhibits plasmin with Ki = 2 nmol/L.a6The mechanism 
differs from the co-amino acids, and the drug may be a 
more effective inhibitor of fibrinolysis within clots than the 
natural plasmin inhibitors, c~2-antiplasmin a d c~2-macro- 
globulin. ~6 Numerous studies conclusively demonstrate 
that systemic aprotinin inhibits fibrinolysisS; Tatar's obser- 
vation that topical aprotinin also inhibits fibrinolysis high- 
lights the question of how it does so. 
Tabuchi and colleagues 17earlier showed that active 
fibrinolysis occurs in pericardial blood during CPB. As 
their adjacent letter notes, 2systemic aprotinin (half-dose 
protocol) halves this activity. Tatar's data suggest hat 
wound fibrinolysis continues after CPB and that topical 
aprotinin reduces postoperative blood loss by inhibiting 
post-CPB fibrinolytic activity. However, aprotinin is a 
small molecule (about 7000 daltons) and probably is 
absorbed from the surface of the heart and pericardium. 
Thus it is not clear whether topical aprotinin acts as a 
topical or systemic agent or both. 
We surgeons must retreat o the bottom line; nothing is 
ever simple in the enzymatic stew of coagulation. If 
subsequent studies confirm the observation that topical 
aprotinin saves a pint of blood per case, why not use it? In 
the meantime, systemic aprotinin remains a proven 
method to reduce blood loss after cardiac operations. 
L. Henry Edmunds, Jr., MD 
Department of Surgery 
4 Silverstein 
Hospital of the University of Pennsylvania 
3400 Spruce St. 
Philadelphia, PA 19104 
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